Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IGC The next GW Pharma located in Maryland not India
Only way it gets to 5.00 level is if it reverse splits
Not out of the question.. these scammers from India want to trap all investors in so they just say f*&k it and stay in..
I'll take my chances at this price. I don't mind losing a couple dollars lmfaohahaha IGC$$$$$$$ the news should be good $5 will not be a penny stock after the newslol
IGC News coming out this week weedTrader420 is a Mastermind TRADER Chuck Berry Run Rudolph Run $5
lmaohahahaha IGC $$$$$$ WOOHOOOO SWEETLEAF
Why do you lie and mislead people? Are you from India? Do you work for them?
this is a penny stock India scam.. it is going much much lower.. you will be able to get it way under .50 if your that stupid
Right on target IGC $3 TO $5 this week
I hope you're right so I could buy more. I can't wait for news this week. FDA approval coming
MAYBE .50
I WILL BET YOU 5000 IT WILL SEE .50 BEFORE 5.00
WANT IT?
IGC $5 TARGET PRICE WOOHOOOOOOOOOOOOOOO
LOL.. HERE IS A SIGN YOUR IN A INDIA STOCK SCAM..
FIRST 8 TRADES ALL BUYS TOTALING ABOUT 400 SHARES
NEXT 5 TRADES ALL SELLS TOTALING ABOUT 51000 SHARES
NO FILING.. NOT CUZ THEY ARE BUSY...LOL THEN WHY NO FILING?
THEY MOST LIKELY HAD TO RE DO TO MAKE SURE ALL THEIR SCAM LIES WERE NOT GOING TO THROW UP RED FLAGS.
SCUMBAGS
THIS ONE IS TOAST..
LATE FILING.. INDIA SCAM HIDING ALL THEY CAN..
TOOK IN MILLIONS OF NEW SHARES SUCKERS ON THE MJ RALLY..
GOING UNDER A DOLLAR TODAY MOST LIKELY..
only MJ stock down.. if it really was a MJ stock..
1.4 million shares sold in last 15 minutes.. someone knows something.. bad news about to hit.
* * $IGC Video Chart 11-06-2020 * *
Link to Video - click here to watch the technical chart video
Just In: $IGC Making A List Of Penny Stocks Right Now? 3 Biotech Stocks To Watch
Are These On Your List Of Penny Stocks To Watch Right Now? If you’re looking for penny stocks to buy right now , you’re likely going to begin with a list. I don’t need to tell you how important a list of penny stocks is during volatile times like these. But ...
Read the whole news IGC - Making A List Of Penny Stocks Right Now? 3 Biotech Stocks To Watch
* * $IGC Video Chart 11-05-2020 * *
Link to Video - click here to watch the technical chart video
I HAVE BEEN IN AND OUT OF THIS ONE A FEW TIMES WHEN IT STARTED ITS RUN. NO BIG LOSS.. I JUST CANT STAND INDIA SCAMS/ CHINA SCAMS.. ECT..
YOU MUST HAVE LOST A BOATLOAD OF $$ IN THIS LOL
LOTS.. THIS IS A PURE SCAM STOCK FROM INDIA. ANYONE WHO IS IN ABOVE 1.55 SAY WILL NEVER EVER GET EVEN... UNLESS THEY WAIT YEARS FOR WHATEVER KNEW THING THEY CAN TAKE ADVANTAGE OF SHEEP WITH.
how many scam companies get FDA approval for phase 1 ???
INDIA SCAM.. DONT GIVE THEM YOUR MONEY..
DONT LET THEM FIX YOUR COMPUTER OVER THE PHONE..LOL
DIRTY FEET SMELLY NO INDOOR TOILETS SCAM ARTISTS.. KEEP YOUR MONEY..
THIS SCAM FROM INDIA WILL BE UNDER 1.20 TODAY...
WRONG.. INDIA SCAM.. WILL BE BACK TO 1.00 THIS WEEK... OR LOWER
$IGC huge MJ stock now coming $3-$5 https://www.ariva.de/india_globalization_capital-aktie/chart
https://www.stockscores.com/charts/charts/?ticker=igc
imho
* * $IGC Video Chart 10-09-2020 * *
Link to Video - click here to watch the technical chart video
GREAT UPTRENDCHART NOW KABOOOOOOM NEXT WEEK
IGC monday over $2 ?
NEWS: $IGC 3 Penny Stocks To Buy For Under $4; Are They Worth The Risk?
Stimulus Talks Spark Optimism for Penny Stocks Technical analysts play a big role for those trading penny stocks . More often than not, your average day trader might not even know what type of company the stock symbol references. The end goal is to profit from its change in pric...
Find out more IGC - 3 Penny Stocks To Buy For Under $4; Are They Worth The Risk?
If you've played this one before, you know it squeezes nicely. :)
$IGC seeing we $2+ today ? WEEEE great chart now , super products , fantastic ss, strong buyers day by day now, first always down then a/h kabooom = everything fits together and maybe a little gem is created here ? ...... soon $5-$10 ?
many big NEWS !!!!
https://www.otcmarkets.com/stock/BIGC/news
$IGC seeing we $2+ today ? WEEEE great chart now , super products , fantastic ss, strong buyers day by day now, first always down then a/h kabooom = everything fits together and maybe a little gem is created here ? ...... soon $5-$10 ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158795587
many big NEWS !!!!
https://www.otcmarkets.com/stock/BIGC/news
I LOAD AND HOLD $$$$$ IGC ( MJ) IS NOW HOT
https://stocktwits.com/symbol/IGC
imho
imo
wow see IGC KABOOOOOOOOOOOM $1,42
IGC LOOKS NOW FANTASTIC - GREAT STOCK NOW -GREAT UPTRENDCHART NOW - STRONG BUY
https://stockcharts.com/h-sc/ui?s=IGC
https://www.ariva.de/india_globalization_capital-aktie/chart
Has great MJ products
Has a dream uptrend chart for days and weeks
Has a lot of imagination
Has a super structure More and more buyers want to be and the stock is making its way,
we will see new ones high.
AGAIN CLOSED ON HIGH - STROOOOOONG BUY NOW
SOOOON $2 - $3 - $5 .....
all only imho
CLOSED ON HIGH $1.42- ONLY BIG BUYERS WOW,
Has great products Has a dream chart for days and weeks Has a lot of imagination has a super structure More and more buyers want to be and the stock is making its way, we will see new ones high has great news this year
IGC LOOKS NOW FANTASTIC - GREAT STOCK NOW -GREAT UPTRENDCHART NOW - STRONG BUY
https://stockcharts.com/h-sc/ui?s=IGC
https://www.ariva.de/india_globalization_capital-aktie/chart
Shorty might think he just dodge a bullet, but there just might be some big after hours attack on him, that blows him out of the water.
By now, the potential for cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD) to reduce the symptoms and even help prevent the onset of diseases such as Alzheimer’s has been fairly well-documented by a wide variety of studies (nnw.fm/RRjS8). The global potential for cannabis-based therapies has triggered a medical marijuana arms race, as countries like Canada, Israel and many of those in Western Europe seize the initiative and more boldly go where the U.S. federal government has feared to allow private industry to tread. Rising stars in the sector, such as phytocannabinoid combination therapy developer India Globalization Capital, Inc. (NYSE MKT: IGC) (IGC Profile), are acutely aware of this immense global potential and have begun to position themselves to secure what will no doubt be hotly-contested market share. Investors interested in medicinal marijuana and/or Alzheimer’s treatments will find themselves looking at a global landscape of key players that includes Medical Marijuana, Inc. (OTC: MJNA), the first U.S. publicly traded cannabis company, as well as Canadian pharmaceutical-grade marijuana producers Aphria, Inc. (OTCQB: APHQF) (TSX: APH), MYM Nutraceuticals, Inc. (OTCQB: MYMMF) (CNSX: MYM) and Supreme Pharmaceuticals, Inc. (OTC: SPRWF) (TSXV: FIRE).
As attitudes grow increasingly favorable to the medicinal capabilities of cannabis, the companies that excel in this new field are those focused on the development of therapies that address global market concerns, such as Alzheimer’s. According to the Alzheimer’s Association, Alzheimer’s disease and other dementias will cost the U.S. roughly $259 billion in 2017 and, by 2050, could rise to as much as $1.1 trillion (http://nnw.fm/OzoX8).
Help may be on the way, though, as India Globalization Capital, Inc. (IGC) is now on the verge of bringing a potential blockbuster treatment for Alzheimer’s to market as soon as early 2018 (http://nnw.fm/8pkAv). Through a license agreement with the University of South Florida (http://nnw.fm/Ny7N0), IGC is the exclusive licensee of the U.S. patent filing “THC as a Potential Therapeutic Agent for Alzheimer’s Disease,” putting the company on track with a unique advantage in the global Alzheimer’s drug market, which is currently valued at roughly $3.6 billion (http://nnw.fm/b6AVl).
Novel in vitro data (http://nnw.fm/wvwX7) aggregated by IGC using genetically engineered cell lines add substantial weight to the existing argument about low doses of THC addressing the link between amyloid beta peptide (Aß plaque) buildup in the cerebral cortex/hippocampus and Alzheimer’s (http://nnw.fm/lnxQ1). Given that the dominant therapies for Alzheimer’s cannot stop or reverse disease progression, the mounting evidence that THC and CBD can stop or even reverse the symptoms of this disease (while providing neuroprotective benefits) is huge (http://nnw.fm/f8RVr).
Today’s dominant Alzheimer’s therapies, such as Allergan’s (AGN) Namenda, Daiichi Sankyo’s (DSNKY, DSKYF) Memary, Novartis’s (NVS) Exelon and the drug Aricept developed by Pfizer (PFE) and Eisai (ESALY, ESALF), may soon find themselves supplanted by disruptive new technologies based on extremely old natural substances, like cannabis, which have been in continuous human use for centuries.
Notably, while IGC’s potential is of impressive significance, the company’s market valuation of $10 million is a drop in a bucket compared to other Alzheimer’s players such as Allergan (NYSE: AGN), valued at $60+ billion; Novartis (NYSE: NVS) at $213 billion, and Pfizer (NYSE: PFE) with a market cap of over $210 billion. While IGC has considerable room to grow as investors become aware of its true value, the company offers potentially the most substantial product in the industry. If its aforementioned patent is approved, IGC will own the key therapeutic pathway by which THC interacts with the human body.
The new in vitro data from IGC extend earlier findings regarding the company’s IGC-AD1 product (Hyalolex, http://nnw.fm/Xb0f4), which showed up to 50 percent reduction in the production of the two key peptides that make up the amyloid plaques found in abundance within the brains of Alzheimer’s patients (http://nnw.fm/o5PGh). Moreover, because Alzheimer’s starts several decades before symptoms begin to exhibit, a drug like IGC-AD1, which has demonstrated an ability to decrease production/aggregation of Aß plaque without neurotoxic effects or inebriation, could become a leading prophylactic treatment taken by millions as a way to prevent Alzheimer’s.
Building on this potential, IGC is gearing up to commercialize a non-inebriating liquid supplement version of the product for the licensed medical dispensary market (http://nnw.fm/4RgWz), which has demonstrated an ability to enhance mitochondrial function (a trigger for Alzheimer’s pathophysiology) by as much as 60 percent in vitro (http://nnw.fm/0kf0N). This readily commercialized combination therapy could give IGC significant, immediate ground game in this burgeoning retail space and help support the company’s clinical work. This one-two punch approach, with a food supplement in one hand and an FDA prophylactic/therapeutic indication in the other, is as powerful as it is solidly backed by exclusively-licensed IP.
Germany alone has nearly 83 million people, and the most common cause behind the 1.6 million-plus dementia cases in that country is Alzheimer’s (http://nnw.fm/Y1F5z). As such, the recent announcement that IGC has entered into an MOU with leading Hamburg-based medical cannabis information and services provider MediCann Handels GmbH (http://nnw.fm/ssMn9) to import and distribute IGC’s cannabinoid-based therapies to German pharmacies has been music to savvy investors’ ears. This is a serious boon for IGC, which marks the first step of many along the company’s path to commercialization and is a real sweetheart of a deal, with MediCann footing the bill for the logistics, as well as sales and marketing.
WRONG.. JUST ANOTHER SCAM FROM INDIA
DISGUSTING BROWN STINKY BAREFOOT SCAMMERS SHITTING IN HOLES IN THEIR BACKYARDS RIPPING OFF AMERICAN INVESTORS.
THEY ARE JUST SMARTER THAN THE "CAR WARRANTY" AND "COMPUTER VIRUS" INDIA LOW LEVEL SCAMMERS.
Got that feeling of the market wasn't getting whacked this stock just might be moving higher, there some big buyer today and yesterday.
Setting up for another run up today, corrupted naked shorting manipulators ran it down this morning to cover shorts, they know if they don't they could end up getting squeezed much higher.
* * $IGC Video Chart 09-03-2020 * *
Link to Video - click here to watch the technical chart video
OR PERHAPS FROM TRIPS BACK TO DOLLARS, DOESN'T THAT SOUND BETTER AND MORE OPTIMISTIC TONE.
IS THERE ANYTHING YOU DO LIKE, FOR SURE NOT LKNCY, IGC OR POAI AT THIS TIME.
Lol.@ "sub penny" area
Sure..why not
From dollars to the trips
Pure genius
Followers
|
184
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9220
|
Created
|
07/17/09
|
Type
|
Free
|
Moderators |
– IGC Pharma to Discuss AI Partnership and Initiatives at Biotech Showcase 2024 –
POTOMAC, MD., December 19, 2023 / IGC Pharma, Inc. (“IGC Pharma” or the “Company”) (NYSE American: IGC), a clinical-stage pharmaceutical company, announced today that Divisional Direction of Patents, Mexico, has issued a Granting Office Action (GOA) for its treatment of Alzheimer’s disease titled “Method and Composition for Treating CNS Disorder.” The Company is optimistic that the success witnessed in Mexico can pave the way for additional approvals in the U.S. and Europe.
IGC Pharma is currently progressing a Phase 2 trial investigating IGC-AD1 as a treatment for agitation in Alzheimer’s disease, the most common form of a central nervous system disorder (CNS). IGC-AD1, the Company’s lead therapeutic candidate, is a partial CB1 receptor agonist designed with anti-neuroinflammatory properties to address the underlying neurodegeneration resulting in neuropsychiatric symptoms. IGC Pharma has strategically sought patent protection for the IGC-AD1 formulation in many jurisdictions including the U.S., Europe, Canada, and Mexico. Today’s announcement of the issuance of the patent for the drug formulation that targets Central Nervous System (CNS) Disorders marks an important milestone in helping set the stage for potential commercialization.
Alzheimer’s disease is a global public health issue affecting an increasing number of individuals as the population ages. According to the Alzheimer’s Association, by 2050, nearly 13 million Americans will be grappling with Alzheimer’s, and related costs are projected to soar to $1 trillion. The burden extends beyond the individual to families, caregivers, and society at large, with approximately 76% of Alzheimer’s patients experiencing neuropsychiatric symptoms such as agitation.
IGC-AD1 is designed to potentially revolutionize the treatment of Alzheimer’s by improving the quality of life of millions of individuals affected by this devastating disease. The current Phase 2 trial, alongside future investigations, aims to validate the effectiveness of IGC-AD1 in managing agitation in Alzheimer’s and relieving caregiver burden.
IGC Pharma is currently pursuing five drug assets targeting the treatment of agitation related to symptoms of Alzheimer’s disease. These assets include IGC-AD1, TGR-63, LMP, IGC-1C, and IGC-M3, all of which are currently in different stages of clinical trials and development.
About IGC Pharma Inc. (dba IGC):
IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. IGC Pharma’s portfolio comprises of five assets, all with a singular mission – to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is a CB1r partial agonist currently in a Phase 2b clinical trial for agitation in dementia due to Alzheimer’s (clinicaltrials.gov, NCT05543681). TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles in a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of Generative AI development, with projects including clinical trials, early detection of Alzheimer’s, and drug interactions with cannabinoids.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |